SCHEDULE: Paulson & Co. Boosts Bausch Health Stake to 19.1%

Paulson & Co. Inc. has significantly increased its beneficial ownership in Bausch Health Companies Inc. to 19.1% through recent share purchases.

Summary

• Paulson & Co. Inc. reported beneficial ownership of 70,755,869 common shares of Bausch Health Companies Inc.
• This represents approximately 19.1% of Bausch Health's outstanding common shares, based on 369,790,319 shares outstanding as of July 25, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed on July 31, 2025.
• The reporting person acquired a total of 37,964,167 common shares between August 11, 2025, and August 14, 2025.
• Key purchases included 2,000,000 shares at $6.35 on August 11, 2025, 1,156,640 shares at $6.88 on August 12, 2025, 86,409 shares at $7.06 on August 13, 2025, and a large block of 34,721,118 shares at $9.00 on August 14, 2025.

Sentiment

Score: 7

Explanation: The significant increase in beneficial ownership by Paulson & Co. Inc. to 19.1% suggests strong investor confidence in Bausch Health Companies Inc., potentially signaling future strategic initiatives or value unlocking.

Positives

• A significant increase in ownership by a prominent investment firm like Paulson & Co. Inc. can signal confidence in Bausch Health's future prospects.
• The substantial investment by Paulson & Co. Inc. could potentially lead to increased shareholder activism or strategic influence, which might drive value creation.

Negatives

• The large purchase on August 14, 2025, at $9.00 per share, is significantly higher than the previous days' purchase prices, indicating a rapid increase in the stock price during the acquisition period, which could imply Paulson was buying into a rising market, potentially at a less favorable average price.

Risks

• The filing itself does not detail company-specific operational risks, but a large concentrated ownership by an investment firm could introduce risks related to activist investor strategies or potential disagreements with existing management.

Future Outlook

The filing is a Schedule 13D, which primarily reports ownership changes. It does not contain forward-looking statements or guidance from the issuer or the reporting person regarding the issuer's future performance.

Industry Context

This filing indicates a significant investment by a major hedge fund in a pharmaceutical and healthcare company. Such large stakes can sometimes precede activist campaigns aimed at influencing corporate strategy, asset divestitures, or governance changes within the healthcare industry, which is currently undergoing significant M&A activity and strategic realignments.

Comparison to Industry Standards

• Paulson & Co. Inc. is known for its activist investing and deep value strategies, often taking significant stakes in companies like Bausch Health. This level of ownership (19.1%) is substantial and positions Paulson as a key stakeholder, similar to how other activist funds like Starboard Value or Elliott Management take large positions to influence companies in various sectors, including healthcare.
• The average price paid for the shares, particularly the large block at $9.00, suggests a strong conviction in Bausch Health's valuation or future potential, especially when compared to the lower prices paid just days prior. This aggressive accumulation is typical of activist investors building a position.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased investor confidence and possible future activist engagement aimed at enhancing shareholder value.
• Management: May face increased scrutiny or pressure from a significant new shareholder.

Key Dates

Recommendation

Paulson & Co. Inc.'s substantial increase in its stake to 19.1% in Bausch Health Companies Inc. indicates strong conviction from a prominent investment firm, which could be a positive signal for the company's future. However, this filing primarily reports an ownership change and does not provide new operational or financial performance data. The stock price has already seen an upward movement during Paulson's accumulation period, as evidenced by the increasing purchase prices. Investors should hold to observe if Paulson & Co. initiates any strategic changes or if Bausch Health's operational performance improves, which would justify a stronger recommendation.

Keywords

Bausch Health, Paulson & Co., Schedule 13D, Shareholder Ownership, Investment Firm, Common Shares, Pharmaceuticals, Healthcare Investment